Evidence map›Paper›PMID 35745214›Full record

Trial reportNutrients2022

Effects of

Sung-Joon Mo, Kippeum Lee, Hyoung-Ju Hong, Dong-Ki Hong, Seung-Hee Jung, Soo-Dong Park, Jae-Jung Shim, Jung-Lyoul Lee

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07720232 (Effect of Bacillus Subtilis and Enterococcus Faecium Combination Therapy Combined With Conventional Lipid-Lowering Treatment on Triglyceride Levels in Patients With Hypertriglyceridemic Acute Pancreatitis), which is not on this map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07720232 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

Effect of Bacillus Subtilis and Enterococcus Faecium Combination Therapy Combined With Conventional Lipid-Lowering Treatment on Triglyceride Levels in Patients With Hypertriglyceridemic Acute Pancreatitis: A Prospective Randomized Controlled Trial

TypeinterventionalSponsorJianyin ZhouRan2026 to 2029Enrolled180ConditionsHypertriglyceridemic Acute Pancreatitis, Acute Pancreatitis, Hypertriglyceridemia-induced, HyperlipidemiaArmsLive Combined Bacillus subtilis and Enterococcus faecium Enteric-coated Capsules (LCBE), Standard Care (in control arm)
3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. ProbioticNarra J · 2025
    Pooled it
  4. The Role ofInternational journal of molecular sciences · 2024
    Pooled it
  5. Effect ofNutrients · 2026
    Trial
  6. Trial
  7. Trial
  8. Plant-DerivedNutrients · 2022
    Trial
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sung-Joon MoR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.ORCID 0000-0001-7687-4861
Kippeum LeeR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.ORCID 0000-0002-1576-7373
Hyoung-Ju HongDepartment of Gastroenterology, Vievis Namuh Hospital, 627, Nonhyeon-ro, Gangnam-gu, Seoul 06117, Korea.
Dong-Ki HongR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.
Seung-Hee JungR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.
Soo-Dong ParkR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.
Jae-Jung ShimR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.
Jung-Lyoul LeeR&BD Center, Hy Co., Ltd., 22, Giheungdanji-ro 24beon-gil, Giheung-gu, Yongin-si 17086, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Obesity and overweight are closely related to diet, and the gut microbiota play an important role in body weight and human health. The aim of this study was to explore how Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032 supplementation alleviate obesity by modulating the human gut microbiome. A randomized, double-blind, placebo-controlled study was conducted on 72 individuals with overweight. Over a 12-week period, probiotic groups consumed 1 × 1010 colony-forming units of HY7601 and KY1032, whereas the placebo group consumed the same product without probiotics. After treatment, the probiotic group displayed a reduction in body weight (p < 0.001), visceral fat mass (p < 0.025), and waist circumference (p < 0.007), and an increase in adiponectin (p < 0.046), compared with the placebo group. Additionally, HY7601 and KY1032 supplementation modulated bacterial gut microbiota characteristics and beta diversity by increasing Bifidobacteriaceae and Akkermansiaceae and decreasing Prevotellaceae and Selenomonadaceae. In summary, HY7601 and KY1032 probiotics exert anti-obesity effects by regulating the gut microbiota; hence, they have therapeutic potential for preventing or alleviating obesity and living with overweight.

Indexed as

Gastrointestinal MicrobiomeLactiplantibacillus plantarumProbioticsBody WeightDouble-Blind MethodHumansLactobacillaceaeLactobacillusObesityOverweightTriglyceridesTriglyceridesbody weightgut microbiotaLactobacillus curvatus HY7601Lactobacillus plantarum KY1032obesityoverweightprobiotics

Identifiers

PMID35745214
PMCPMC9228474
OpenAlexW4283016962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.